The Future of RRFL: Personalized Treatment, Novel Agents, and Moving Beyond Chemotherapy

In 'The Future of RRFL: Personalized Treatment, Novel Agents, and Moving Beyond Chemotherapy,' Christina Poh, MD delves into the following critical question:

Reflecting on all the studies we discussed today, what would be your main takeaways about the landscape of therapies for RRFL?

Led by the moderator, Christina Poh shared her closing reflections on the relapsed or refractory follicular lymphoma treatment landscape, expressing strong optimism about both the current state and near-term future of the field, noting that the development of many novel, highly effective treatment options over the past several years has fundamentally transformed what is possible for patients with this chronic, relapsing disease. She emphasized that the breadth and quality of available therapies now makes this an opportune moment to move away from conventional chemotherapy regimens that carry risks of long-term side effects and secondary malignancies, in favor of more targeted, better-tolerated approaches that can be meaningfully personalized to each patient.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Treating RRFL in the Community: How Patient Profiles and Disease Trajectory Shape Treatment Decisions,' features Tara Graff, DO, MS sharing her perspective as a community oncologist on follicular lymphoma, discussing how the RRFL patient population in community practice compares to academic trial settings, the importance of recognizing POD24 patients and treating them more aggressively, and the patient-specific factors, including age, comorbidities, and quality of life goals, that most commonly drive treatment decisions at first and subsequent relapse in the community setting.